Press Releases April 29, 2026 04:15 PM

FTAI Upsizes Revolving Credit Facility to Over $2 Billion

FTAI Aviation significantly increases revolving credit facility to $2.025 billion, enhancing financial flexibility for growth.

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
FTAI

FTAI Aviation Ltd. announced the upsizing and extension of its revolving credit facility from $400 million to $2.025 billion, with maturity extended to April 2031. The facility, oversubscribed and led by major banks including JPMorgan Chase, positions FTAI to pursue growth opportunities with lower borrowing costs. The company emphasizes improved terms and financial agility to capitalize on market opportunities and deliver long-term shareholder value.

FTAI Upsizes Revolving Credit Facility to Over $2 Billion
FTAI
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • FTAI increased its revolving credit facility by over five times to $2.025 billion with extended maturity to 2031.
  • The financing package involves a broad syndicate of major domestic and international banks, indicating strong lender confidence.
  • Lower borrowing costs and increased liquidity will allow FTAI to pursue growth opportunities proactively in aviation and related sectors.

NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- FTAI Aviation Ltd. (NASDAQ: FTAI; the "Company" or “FTAI”) today announced that it has amended and extended its existing revolving credit facility 2031 (the “Facility”), increasing total commitments from $400 million to $2.025 billion and extending the maturity to April. The Facility is led by JPMorgan Chase Bank as Administrative Agent and BNP Paribas, Citibank, MUFG Bank, PNC Bank and Royal Bank of Canada as Syndication Agents. Other banks participating include Barclays, Citizens Bank, Deutsche Bank, Goldman Sachs and Truist Bank as Co-Documentation Agents, as well as Capital One, Standard Chartered and U.S. Bank.

The Facility was oversubscribed and is a record size for FTAI, positioning the Company to pursue compelling opportunities in the market to deliver sustained growth and long-term value for its shareholders.

“We are pleased to complete the upsize of our revolving credit facility and thank our banking partners for their support and confidence in our business,” said Nicholas McAleese, Chief Financial Officer of FTAI. “The increased size, combined with improved pricing terms that reduce our cost of borrowing, will support the overall growth objectives of our business and allow us to be nimble when attractive opportunities arise.”

About FTAI

FTAI combines advanced turbine technology and asset ownership to power the world’s most essential markets. Additional information is available at https://www.ftaiaviation.com.

For further information, please contact:
Alan Andreini
Investor Relations
FTAI Aviation Ltd.
(646) 734-9414
aandreini@ftaiaviation.com

Media:
Tim Lynch / Kelly Sullivan
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449


Risks

  • Increased debt levels may elevate financial leverage and risk, especially if market opportunities do not materialize as expected.
  • Dependence on credit markets for growth financing exposes the company to fluctuations in interest rates and lending conditions.
  • Ability to deploy the raised credit facility efficiently will impact financial performance and shareholder value realization.

More from Press Releases

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026 Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism Jun 13, 2026 Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026